{"entity":{"id":"paper-aurelia-jco-2014","kind":"paper","name":"AURELIA: bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer","aka":[],"tldr":"Adding bevacizumab to single-agent chemotherapy doubled the time to progression and the response rate in platinum-resistant ovarian cancer, becoming the first regimen to improve outcomes in this hard-to-treat setting.","summary":"Phase 3 trial of 361 patients with platinum-resistant ovarian cancer (progression within six months of platinum) and up to two prior regimens randomised to weekly paclitaxel, pegylated liposomal doxorubicin or topotecan with or without bevacizumab.\n\nMedian progression-free survival was 6.7 versus 3.4 months (hazard ratio 0.48) and objective response 27.3 versus 11.8 percent; overall survival was not significantly improved (16.6 versus 13.3 months), partly because of crossover.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2014","url":"https://doi.org/10.1200/JCO.2013.51.4489"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/24637997/"}],"tags":[],"related":[],"cancers":["platinum-resistant-ovarian-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2014,"doi":"10.1200/JCO.2013.51.4489","pmid":"24637997","authors":"Pujade-Lauraine E, Hilpert F, Weber B, et al.","paperType":"rct","findings":["Median progression-free survival 6.7 vs 3.4 months; hazard ratio 0.48.","Objective response 27.3 percent vs 11.8 percent."],"whatItMeans":"Bevacizumab with weekly paclitaxel or other single agents is a standard for platinum-resistant ovarian cancer in bevacizumab-naive patients, and the control regimen for later trials such as MIRASOL and ROSELLA.","caveats":["No significant overall survival benefit.","Patients with bowel involvement were excluded because of perforation risk."],"changedPractice":true,"participants":361},"route":"/key-papers/paper-aurelia-jco-2014/","neighbours":{"cancer":[{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}